Clinical Trial

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-20; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2025-05-30
Trial Details
NCT Number NCT06839105
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Enrollment 214 participants
Start Date 2025-02-21
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02